Original Paper
Ocular Erythropoietin Penetration after Subconjunctival Administration in Glaucomatous RatsResende A.P. · São Braz B. · Delgado E.Departamento de Clínica, CIISA, Faculty of Veterinary Medicine, University of Lisbon, Lisbon, Portugal
|
|
Do you have an account?
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: September 10, 2015
Accepted: January 29, 2016
Published online: April 15, 2016
Issue release date: July 2016
Number of Print Pages: 7
Number of Figures: 5
Number of Tables: 2
ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)
For additional information: https://www.karger.com/ORE
Abstract
Purpose: The present study aimed to determine whether the subconjunctival administration of recombinant human erythropoietin (rHuEPO) reached the retina in glaucoma conditions. After subconjunctival rHuEPO administration, in a rat glaucoma model, erythropoietin (EPO) distribution in the rat's retina was studied by immunohistochemistry. Methods: Female Wistar Hannover albino rats (n = 15) were divided into 2 groups, control (n = 3) and treated (n = 12). The animals' unilateral glaucoma was induced by coagulation of episcleral veins, under general anaesthesia. After vein coagulation, 1,000 IU of rHuEPO were administered by the subconjunctival route to the treated group (n = 12). The control group (n = 3) received only a subconjunctival saline injection. The contralateral eye of each animal remained untouched. Treated group animals were euthanized at different time points, i.e. days 1, 3, 7 and 14. Bilateral enucleation was performed, and EPO distribution in the rat's retina was assessed by immunohistochemistry. Results: Glaucoma was confirmed by results of repeated intraocular pressure measurements over the experimental period. In the test group, EPO was identified in different neuroretinal cells, showing a stronger immunostaining signal during the first 2 time points in the retinal ganglion cell (RGC) layer. EPO protein was still present on day 14 after the subconjunctival injection. EPO was not detected in any of the control eyes or in any contralateral eye of the treated group. Conclusion: When administered subconjunctivally to glaucomatous eyes, rHuEPO reached the RGC layer and was still present at least 14 days after administration. The subconjunctival route was shown to be a promising alternative for ocular EPO delivery in glaucomatous conditions in a rat animal model.
© 2016 S. Karger AG, Basel
Related Articles:
References
- Quigley HA, Broman AT: The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-267.
- Almasieh M, Wilson AM, Morquette B, Cueva Vargas JL, Di Polo A: The molecular basis of retinal ganglion cell death in glaucoma. Prog Retin Eye Res 2012;31:152-181.
- Laquis S, Chaudhary P, Sharma SC: The patterns of retinal ganglion cell death in hypertensive eyes. Brain Res 1998;784:100-104.
- Almasieh M, Zhou Y, Kelly ME, Casanova C, Di Polo A: Structural and functional neuroprotection in glaucoma: role of galantamine-mediated activation of muscarinic acetylcholine receptors. Cell Death Dis 2010;1:e27.
- Cheung W, Guo L, Cordeiro MF: Neuroprotection in glaucoma: drug-based approaches. Optom Vis Sci 2008;85:406-416.
- Grasso G, Sfacteria A, Meli F, et al: The role of erythropoietin in neuroprotection: therapeutic perspectives. Drug News Perspect 2007;20:315-320.
- Bartesaghi S, Marinovich M, Corsini E, Galli CL, Viviani B: Erythropoietin: a novel neuroprotective cytokine. Neurotoxicology 2005;26:923-928.
- Sättler MB, Merkler D, Maier K, et al: Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 2004;11(suppl 2):S181-S192.
- Kumral A, Genc S, Ozer E, et al: Erythropoietin downregulates bax and DP5 proapoptotic gene expression in neonatal hypoxic-ischemic brain injury. Biol Neonate 2006;89:205-210.
- Tsai JC, Wu L, Worgul B, Forbes M, Cao J: Intravitreal administration of erythropoietin and preservation of retinal ganglion cells in an experimental rat model of glaucoma. Curr Eye Res 2005;30:1025-1031.
- Tsai JC, Song BJ, Wu L, Forbes M: Erythropoietin: a candidate neuroprotective agent in the treatment of glaucoma. J Glaucoma 2007;16:567-571.
- Song BJ, Cai H, Tsai JC, Chang S, Forbes M, Del Priore LV: Intravitreal recombinant human erythropoietin: a safety study in rabbits. Curr Eye Res 2008;33:750-760.
- Zhang J, Wu Y, Jin Y, et al: Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci 2008;49:732-742.
- Luo W, Hu L, Wang F: The protective effect of erythropoietin on the retina. Ophthalmic Res 2015;53:74-81.
- Lagrèze WA, Feltgen N, Bach M, Jehle T: Feasibility of intravitreal erythropoietin injections in humans. Br J Ophthalmol 2009;93:1667-1671.
- Zhong Y-S, Liu X-H, Cheng Y, Min Y-J: Erythropoietin with retrobulbar administration protects retinal ganglion cells from acute elevated intraocular pressure in rats. J Ocul Pharmacol Ther 2008;24:453-459.
- Geroski DH, Edelhauser HF: Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci 2000;41:961-964.
- Resende AP, São-Braz B, Delgado E: Alternative route for erythropoietin ocular administration. Graefes Arch Clin Exp Ophthalmol 2013;251:2051-2056.
- Shareef SR, Garcia-Valenzuela E, Salierno A, Walsh J, Sharma SC: Chronic ocular hypertension following episcleral venous occlusion in rats. Exp Eye Res 1995;61:379-382.
- Bond WS, Rex TS: Evidence that erythropoietin modulates neuro-inflammation through differential action on neurons, astrocytes, and microglia. Front Immunol 2014;22:523.
- Zhang C, Wang H, Nie J, Wang F: Protective factors in diabetic retinopathy: focus on blood-retinal barrier. Discov Med 2014;18:105-112.
- Gui DM, Yang Y, Li X, Gao DW: Effect of erythropoietin on the expression of HIF-1 and iNOS in retina in chronic ocular hypertension rats. Int J Ophthalmol 2011;4:40-43.
- Grozdanic SD, Betts DM, Sakaguchi DS, Kwon YH, Kardon RH, Sonea IM: Temporary elevation of the intraocular pressure by cauterization of vortex and episcleral veins in rats causes functional deficits in the retina and optic nerve. Exp Eye Res 2003;77:27-33.
- Doh SH, Kim JH, Lee KM, Park HY, Park CK: Retinal ganglion cell death induced by endoplasmic reticulum stress in a chronic glaucoma model. Brain Res 2010;1308:158-166.
- Danias J, Shen F, Kavalarakis M, et al: Characterization of retinal damage in the episcleral vein cauterization rat glaucoma model. Exp Eye Res 2007;82:219-228.
- Morrison JC, Cepurna WO, Guo Y, Johnson EC: Pathophysiology of human glaucomatous optic nerve damage: insights from rodent models of glaucoma. Exp Eye Res 2011;93:156-164.
- King CE, Rodger J, Bartlett C, Esmaili T, Dunlop SA, Beazley LD: Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection. Exp Neurol 2007;205:48-55.
- Zhong Y, Yao H, Deng L, Cheng Y, Zhou X: Promotion of neurite outgrowth and protective effect of erythropoietin on the retinal neurons of rats. Graefes Arch Clin Exp Ophthalmol 2007;245:1859-1867.
Article / Publication Details
Received: September 10, 2015
Accepted: January 29, 2016
Published online: April 15, 2016
Issue release date: July 2016
Number of Print Pages: 7
Number of Figures: 5
Number of Tables: 2
ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)
For additional information: https://www.karger.com/ORE
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID